Kaur Simrat, Nagaraja Vinayak, Schoenhagen Paul, Dabbagh M Marwan, Bazarbashi Najdat, Khubber Shameer, Kaur Manpreet, Mohomad Gad, Verma Beni, Yun James, Svensson Lars, Tuzcu Murat, Popović Zoran B, Krishnaswamy Amar, Kapadia Samir
Department of Cardiology, Section of Cardiovascular Medicine Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Interventional Cardiology, Section of Interventional Cardiology, Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Struct Heart. 2024 Aug 19;9(2):100356. doi: 10.1016/j.shj.2024.100356. eCollection 2025 Feb.
Cardiac tamponade is a rare but potentially lethal complication of transcatheter aortic valve replacement (TAVR). There is paucity of evidence assessing the incidence and outcomes of patients with cardiac tamponade after TAVR.
A retrospective review was performed of all patients who underwent TAVR at our institution from January 2013 to January 2019. The clinical characteristics of patients who developed cardiac tamponade in the periprocedural period were compared to the patients who did not develop tamponade. Qualitative and quantitative assessment of aortic annular calcium distribution on cardiac computerized tomography was analyzed.
Twenty out of 2030 patients (0.9%) developed cardiac tamponade post-TAVR. The mean age of the cohort developing cardiac tamponade was 81.7 years, and 50% of them were men. Most of these were intraprocedural (70%) while the remaining were identified in the postprocedural period. The site of injury resulting in pericardial tamponade was thought to be from the injury to aortic annulus (50%), right ventricle (40%), and left ventricle (10%). Tamponade due to annular or left ventricular trauma was mostly identified intraprocedurally (91%; n = 10 of 11), while patients with tamponade due to presumed right ventricular injury were mostly identified in the postprocedural period (62.5%; n = 5 of 8) ( = 0.009). Conservative management with supportive therapies was employed in 90% of patients with cardiac tamponade, while two patients had cardiac surgery. There was one in-hospital mortality, and another patient died within 30 days of the TAVR procedure.
The incidence of cardiac tamponade after TAVR (0.9%) was low, and this serious complication can be managed successfully in the majority of patients with streamlined processes in high-volume centers.
心脏压塞是经导管主动脉瓣置换术(TAVR)一种罕见但可能致命的并发症。评估TAVR术后发生心脏压塞患者的发病率和预后的证据较少。
对2013年1月至2019年1月在我院接受TAVR的所有患者进行回顾性研究。将围手术期发生心脏压塞的患者的临床特征与未发生压塞的患者进行比较。对心脏计算机断层扫描上主动脉瓣环钙化分布进行定性和定量分析。
2030例患者中有20例(0.9%)在TAVR术后发生心脏压塞。发生心脏压塞的队列的平均年龄为81.7岁,其中50%为男性。这些患者大多数是在手术过程中(70%)发生的,其余的是在术后阶段发现的。导致心包压塞的损伤部位被认为是主动脉瓣环损伤(50%)、右心室(40%)和左心室(10%)。由于瓣环或左心室创伤导致的压塞大多在手术过程中发现(91%;11例中的10例),而因推测右心室损伤导致压塞的患者大多在术后阶段发现(62.5%;8例中的5例)(P = 0.009)。90%的心脏压塞患者采用支持性治疗的保守管理方法,而两名患者接受了心脏手术。有1例住院死亡,另1例患者在TAVR手术后30天内死亡。
TAVR术后心脏压塞的发生率(0.9%)较低,在大多数患者中,通过高容量中心简化的流程可以成功处理这种严重并发症。